EUVIMEDEUVIMED entdecken
Crossref

RED CELL ALLOIMMUNIZATION IN MULTI TRANSFUSED ONCOLOGY PATIENTS IN A TERTIARY CARE HOSPITAL

Harsha Unni, Meena D

INDIAN JOURNAL OF APPLIED RESEARCH · 01.01.2024 · 78-80

DOI: 10.36106/ijar/3702879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift INDIAN JOURNAL OF APPLIED RESEARCH, online erschienen am 01.01.2024. Verfasst von Harsha Unni und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Blood transfusion is an integral part of multifaceted therapy in oncology patients owing to the intense marrow suppression resulting from chemotherapy, radiotherapy, or disease pathology. Transfusion dependence exposes these patients to consequences of blood transfusion including alloimmunization against one or more red cell antigens. Alloimmunization can result in delayed hemolytic transfusion reactions on subsequent transfusion of antigen- positive donor RBCs.

Objectives

To assess the factors and their association with the development of antibodies in multiple transfused individuals. Materials & Methods: A hospital-based Descriptive Study was conducted among 100 multi-transfused oncology patients. All oncology patients aged above 18 years who had received ≥ 2 packed red blood cell transfusions were included, and post-hematopoietic stem cell transplant patients were excluded. After obtaining informed consent, blood grouping, Rh typing and antibody screening were performed on all blood samples. Antibody identication of screening positive samples was done using a commercial 11-cell panel of reagent red cells (BioradID Dia-panel). The statistical analysis was done using SPSS version 22.0 software. In the study population, only 1% of multi-transfused oncology patients Results: developed alloimmunization. The association of alloimmunization with the total number of transfusions (p value = 0.017) and, the cumulative number of PRC and PC transfusions (p value = 0.045) is statistically signicant in this study. The mode of cancer treatment undergone by the patient also has a signicant association with the total number of transfusions received by the patient. The rate of alloi Conclusion: mmunization is low (1%) in multi-transfused oncology patients. Routine pretransfusion antibody screening before crossmatching on patient blood samples should be mandated as part of pretransfusion testing in multi-transfused patients to ensure transfusion safety.

Zitieren

APA

Unni, H., & D, M. (2024). RED CELL ALLOIMMUNIZATION IN MULTI TRANSFUSED ONCOLOGY PATIENTS IN A TERTIARY CARE HOSPITAL. INDIAN JOURNAL OF APPLIED RESEARCH, 78-80. https://doi.org/10.36106/ijar/3702879

Vancouver

Unni H, D M. RED CELL ALLOIMMUNIZATION IN MULTI TRANSFUSED ONCOLOGY PATIENTS IN A TERTIARY CARE HOSPITAL. INDIAN JOURNAL OF APPLIED RESEARCH. 2024:78-80. doi:10.36106/ijar/3702879

BibTeX
@article{Unni2024,
  author = {Unni, Harsha and D, Meena},
  title = {RED CELL ALLOIMMUNIZATION IN MULTI TRANSFUSED ONCOLOGY PATIENTS IN A TERTIARY CARE HOSPITAL},
  journal = {INDIAN JOURNAL OF APPLIED RESEARCH},
  year = {2024},
  pages = {78--80},
  doi = {10.36106/ijar/3702879}
}
Kostenlos starten →